 |
| 06-Jun-13 | Reiterated |
MLV & Co |
Buy |
$18.50 → $16 |
|
| 01-Apr-13 | Reiterated |
MLV & Co |
Buy |
$16 → $18.50 |
|
| 30-Aug-12 | Initiated |
Stifel Nicolaus |
Hold |
|
|
| 05-Jan-12 | Initiated |
Rodman & Renshaw |
Mkt Outperform |
$8 |
|
| 14-Mar-11 | Reiterated |
Barclays Capital |
Equal Weight |
$2 → $4 |
|
| 28-Feb-11 | Upgrade |
Canaccord Genuity |
Hold → Buy |
$4.50 → $8 |
|
| 09-Nov-10 | Initiated |
MLV Capital |
Buy |
$8.50 |
|
| 26-Aug-10 | Initiated |
Morgan Joseph |
Buy |
$6 |
|
| 10-May-10 | Upgrade |
Roth Capital |
Hold → Buy |
$4 |
|
| 19-Feb-10 | Initiated |
RBC Capital Mkts |
Sector Perform |
$5 |
|
| 17-Feb-10 | Downgrade |
Roth Capital |
Buy → Hold |
$4 |
|
| 05-Nov-09 | Upgrade |
Roth Capital |
Hold → Buy |
$2 → $4 |
|
| 27-Feb-09 | Downgrade |
Wachovia |
Mkt Perform → Underperform |
|
|
| 27-Feb-09 | Downgrade |
Roth Capital |
Buy → Hold |
$11 → $2 |
|
| 27-Feb-09 | Downgrade |
Rodman & Renshaw |
Mkt Outperform → Mkt Perform |
|
|
| 27-Feb-09 | Downgrade |
RBC Capital Mkts |
Outperform → Sector Perform |
|
|
| 27-Feb-09 | Downgrade |
Lazard Capital |
Buy → Hold |
|
|
| 01-Dec-08 | Initiated |
Banc of America Sec |
Neutral |
|
|
| 20-Nov-08 | Reiterated |
Rodman & Renshaw |
Mkt Outperform |
|
|
| 06-Nov-08 | Initiated |
Wachovia |
Mkt Perform |
|
|
|
|
| 17-Jun-13 10:17AM | SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submi EDGAR Online |
| 14-Jun-13 05:01PM | 3 Horrendous Health-Care Stocks This Week at Motley Fool |
| 10-Jun-13 12:51PM | Infinity Pharma's Safety Concerns: For Patient Investors, A Buying Opportunity at Seeking Alpha |
| 09-Jun-13 08:17AM | 3 Healthcare Companies With Recent Intensive Insider Buying at Seeking Alpha |
| 07:15AM | 5 of Last Week's Biggest Losers at Motley Fool |
| 08-Jun-13 12:05PM | All About ASCO: 2013 Highlights at Motley Fool |
| 09:15AM | 3 Horrendous Health-Care Stocks This Week at Motley Fool |
| 07:00AM | The Best- And Worst-Performing Biotech Stocks, May 31 To June 7 at Forbes |
| 07-Jun-13 11:31AM | Pepsi Turns Eyes to China, Syntas Insider Trades and 3 More Hot Stocks at Wall St. Cheat Sheet |
| 11:04AM | Synta Pharmaceuticals Director Buys 756K Shares and 3 Insider Buys to Note at Wall St. Cheat Sheet |
| 07:00AM | The 5 Dumbest Things on Wall Street This Week: June 7 at TheStreet |
| 05:30AM | [video] 5 Dumbest Things on Wall Street at TheStreet |
| 05-Jun-13 11:34AM | Post-ASCO Movers: Are Any a Buy? at Motley Fool -7.24% |
| 07:57AM | Monday's Top Biotech Losers Infinity And Synta And Other Top Sells By Fund Managers at Seeking Alpha |
| 04-Jun-13 06:20PM | Synta Pharmaceuticals Corp. - Special Call at Seeking Alpha |
| 06:20PM | Synta Pharmaceuticals' CEO Hosts Investor Meeting at the 2013 ASCO Annual Meeting (Transcript) at Seeking Alpha |
| 10:25AM | Synta Pharmaceuticals: A Promising Biotech Stock for 2013 at Motley Fool |
| 08:00AM | Synta to Present at the Jefferies 2013 Global Healthcare Conference Business Wire |
| 03-Jun-13 04:48PM | Synta Falls as Study Shows Less Cancer Survival Benefit at Bloomberg -34.01% |
| 03:11PM | Why Synta Pharmaceuticals Shares Imploded at Motley Fool |
| 11:02AM | Synta shares fall after lung cancer trial results at Reuters |
| 10:47AM | SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 09:18AM | Synta's Lung Cancer Drug Struggles to Remain Relevant at TheStreet |
| 09:06AM | Stocks to Watch: Cracker Barrel, Synta Pharma, Affymax at The Wall Street Journal |
| 07:34AM | InPlay: Synta announces positive overall survival results from GALAXY-1 Phase 2b/3 trial of ganetespib in second-line non-small cell lung cancer Briefing.com |
| 07:34AM | Synta Announces Positive Overall Survival Results From GALAXY-1 Phase 2b/3 Trial of Ganetespib in Second-Line Non-Small Cell Lung Cancer Business Wire |
| 07:30AM | Synta drug shown to extend lives of certain lung cancer patients at Reuters |
| 07:30AM | Synta's Lung Cancer Drug Struggles to Remain Relevant at TheStreet |
| 07:30AM | Synta Lung Cancer Treatment Helps Boost Survival, Study Shows at Bloomberg |
| 31-May-13 04:03PM | Synta to Host Investor Meeting and Webcast at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting Business Wire |
| 08:03AM | 5 Worst Biotechs of 2013 at Motley Fool |
| 23-May-13 02:19PM | Commit To Buy Synta Pharmaceuticals At $5, Earn 97.3% Annualized at TheStreet |
| 21-May-13 10:32AM | Hedge Funds Are Buying 5 Highly Shorted And Oversold Stocks On Losing Streaks at Seeking Alpha |
| 20-May-13 11:15AM | 3 Small Cap Cancer Stocks With Upcoming Catalysts at Seeking Alpha |
| 15-May-13 06:30PM | Synta Announces Presentations at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting Business Wire |
| 14-May-13 10:16AM | Synta Is a Run-Up Trade Into ASCO Lung Cancer Data at TheStreet |
| 10-May-13 05:15PM | 3 Horrendous Health-Care Stocks This Week at Motley Fool |
| 07:00AM | Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin at TheStreet |
| 08-May-13 04:35PM | Synta Pharmaceuticals Becomes Oversold (SNTA) at TheStreet -13.38% |
| 07-May-13 01:40PM | Why Synta Pharmaceuticals Shares Sank at Motley Fool -15.47% |
| 06-May-13 10:24AM | SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events EDGAR Online |
| 04-May-13 01:04PM | SYNTA PHARMACEUTICALS CORP Financials EDGAR Online Financials |
| 30-Apr-13 04:30PM | Synta Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 10:00AM | Synta Pharmaceuticals Corp. Earnings Call scheduled for 10:00 am ET today CCBN |
| 07:07AM | Q1 2013 Synta Pharmaceuticals Corp. Earnings Release - Before Market Open CCBN |
| 06:52AM | InPlay: Synta Pharma misses by $0.03; provides clinical update for GALAXY-1 Phase 2b/3 trial Briefing.com |
| 06:45AM | Synta Provides Clinical Updates and Reports First Quarter 2013 Financial Results Business Wire |
| 29-Apr-13 11:14PM | SYNTA PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 07:07PM | Synta Pharmaceuticals Earnings Preview: Get Ahead of the Analysts at Wall St. Cheat Sheet |
| 26-Apr-13 08:15AM | Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail! at TheStreet |
| 22-Apr-13 07:46AM | Synta says first patients treated in GALAXY-2 trial evaluating Ganetespib theflyonthewall.com |
| 07:45AM | Synta Announces First Patients Treated in Pivotal GALAXY-2 Trial Evaluating Ganetespib in Advanced Non-Small Cell Lung Cancer Business Wire |
| 16-Apr-13 07:45AM | Synta to Host Conference Call and Webcast of First Quarter 2013 Financial Results on April 30, 2013 Business Wire |
| 05-Apr-13 04:15PM | Synta Announces Presentations at the 2013 Annual Meeting of the American Association of Cancer Research Business Wire +8.00% |
| 02-Apr-13 02:57PM | Tackling Cancer: Melanoma's Biggest Current & Upcoming Players at Motley Fool |
| 01-Apr-13 03:33PM | BlackBerry Will Underperform and 4 More Analyst Notes to Looks At at Wall St. Cheat Sheet |
| 01:46AM | SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Finan EDGAR Online |
| 29-Mar-13 11:59AM | Tokai promotes Jodie Morrison to CEO at bizjournals.com |
| 25-Mar-13 11:26AM | Synta's Slump On Shelf Registration Provides Entry Point Ahead Of ASCO at Seeking Alpha |
| 19-Mar-13 01:04PM | SYNTA PHARMACEUTICALS CORP Financials EDGAR Online Financials |
| 16-Mar-13 07:32PM | New Star Analyst Rankings for Synta Pharmaceuticals Corp. StarMine |
| 15-Mar-13 07:41PM | New Star Analyst Rankings for Synta Pharmaceuticals Corp. StarMine |
| 11:01AM | Steven Quay, CEO of Atossa Genetics, Inc. (ATOS), Interviews with The Wall Street Transcript Wall Street Transcript |
| 14-Mar-13 04:02PM | Synta Pharma announces new offering, trades lower AP |
| 02:50PM | Why Synta Pharmaceuticals Shares Stumbled at Motley Fool |
| 12:10PM | Synta Pharmaceuticals Management Discusses Q4 2012 Results - Earnings Call Transcript at Seeking Alpha |
| 10:00AM | Q4 and Year-End 2012 Synta Pharmaceuticals Corp. Earnings Call scheduled for 10:00 am ET today CCBN |
| 10:00AM | Hibbett Sports, Inc. Earnings Call scheduled for 10:00 am ET today CCBN |
| 09:49AM | Q4 and Year-End 2012 Synta Pharmaceuticals Corp. Earnings Call scheduled for 10:00 am ET today CCBN |
| 07:52AM | Synta Pharma sees cash resources sufficient to fund operations into 2Q14 at theflyonthewall.com |
| 07:50AM | Synta Provides Company Updates and Reports Fourth Quarter and Year-End 2012 Financial Results Business Wire |
| 07:40AM | Synta Pharmaceuticals files $300M mixed securities shelf theflyonthewall.com |
| 07:22AM | SYNTA PHARMACEUTICALS CORP Files SEC form 10-K, Annual Report EDGAR Online |
| 07:07AM | Q4 2012 Synta Pharmaceuticals Corp. Earnings Release - Before Market Open CCBN |
| 13-Mar-13 05:18PM | InPlay: Synta Pharma announces appointment of Sumant Ramachandra, M.D., Ph.D. as President, Research and Development Briefing.com |
| 05:00PM | SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 04:15PM | Synta Announces Appointment of Sumant Ramachandra, M.D., Ph.D. as President, Research and Development Business Wire |
| 12-Mar-13 06:00PM | Synta Pharmaceuticals Corp. Presents at Barclays Global Healthcare Conference, Mar-12-2013 03:45 PM at Seeking Alpha |
| 11-Mar-13 08:15AM | Outlook for Diagnostic Substances Industry Marketwire |
| 08-Mar-13 07:00PM | 5 Reasons to Worry About Next Week at Motley Fool |
| 05:04PM | SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online |
| 03:15AM | George Zavoico: Biotech Stocks That Deserve A Closer Look at Seeking Alpha |
| 06-Mar-13 01:24PM | Synta plans to enroll first patient in lung cancer trial at bizjournals.com |
| 05-Mar-13 09:28AM | Trius Therapeutics: New MSRA Treatment Could Bring Billions In Revenues at Seeking Alpha +7.34% |
| 28-Feb-13 10:01AM | Synta Pharmaceuticals' Subgroup Selection Strategy Is A Set-Up For Success at Seeking Alpha |
| 25-Feb-13 07:15AM | Synta to Host Conference Call and Webcast of Fourth Quarter and Year-End 2012 Financial Results on March 14, 2013 Business Wire |
| 13-Feb-13 10:06AM | Why Synta Pharmaceuticals Is Poised to Plunge at Motley Fool |
| 11-Feb-13 08:00AM | Synta to Present at Upcoming Conferences Business Wire |
| 30-Jan-13 10:10AM | Insiders Bullish on Certain Holdings of IWC at Forbes |
| 28-Jan-13 08:20AM | Mergers and Acquisitions on the Rise in 2013 as Big Pharma Companies Hold Record Amounts of Cash on Hand Marketwire |
| 24-Jan-13 03:31PM | ARIAD prices $300M stock offering to support launch of leukemia drug at bizjournals.com |
| 23-Jan-13 09:18AM | Insiders Love These 3 Highly Shorted Healthcare Stocks at Seeking Alpha |
| 15-Jan-13 12:09PM | Synta: Share Price Not Reflecting Ganetespib Value Proposition at Seeking Alpha |
| 28-Dec-12 11:41AM | Here's What Graham Capital Management Has Been Buying at Motley Fool |
| 11:37AM | Molecular Therapeutics in Oncology Driving U.S. Biotech Valuations: New Diagnostic Based Therapies Create Defensive Fiscal Cliff Resistant Portfolio Strategy Wall Street Transcript |
| 20-Dec-12 04:12PM | SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E EDGAR Online |
| 14-Dec-12 08:33PM | 3 Humongous Health-Care Stocks This Week at Motley Fool |
| 13-Dec-12 05:07PM | SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St EDGAR Online |
| 02:59PM | Synta to raise $60M through direct stock offering at bizjournals.com |
| 12:30PM | Regeneron Pharmaceuticals and More Big Movers in Healthcare on December 13, 2012 at Investopedia |
|
|
| Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs for treating severe medical conditions, including cancer and chronic inflammatory diseases. The company has two drug candidates in clinical trials for treating multiple types of cancer and various drug candidates in the preclinical stage of development. Its oncology product pipeline includes Ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trials for the treatment of second-line advanced adenocarcinoma non-small cell lung cancer (NSCLC) with adenocarcinoma histology; in Phase IIb/III clinical trials for the treatment of adenocarcinoma NSCLC; in Phase II clinical trials for NSCLC patients whose tumors have a genetic profile characterized by rearrangement of the ALK gene and patients with newly diagnosed HER2+ and triple-negative metastatic breast cancer; in Phase II clinical trials for the treatment of breast cancer, lung cancer, acute myeloid leukemia (AML), and rectal cancer; and in Phase I/II clinical trials for treating mesothelioma and multiple myeloma, as well as has completed Phase II clinical trials for treating NSCLC. The company's product pipeline also comprises additional Hsp90 inhibitors, which are in preclinical development stage for cancer; Elesclomol, a mitochondria-targeting agent that is in Phase I/II clinical trials for ovarian cancer and Phase I clinical trials for AML; and STA-9584, a vascular disrupting agent in preclinical development stage for prostate cancer. Its product pipeline for inflammatory diseases includes CRACM ion channel inhibitors in preclinical development stage for autoimmune diseases, respiratory conditions, and transplantation; and IL-12/23 inhibitors in lead optimization stage for autoimmune diseases. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Bahcall Safi R | President and CEO | Jun 14 | Buy | 4.06 | 10,000 | 40,550 | 2,003,135 | Jun 17 08:02 AM | | Bahcall Safi R | President and CEO | Jun 06 | Buy | 4.04 | 10,000 | 40,390 | 1,993,135 | Jun 06 05:19 PM | | Kovner Bruce | Director | Jun 06 | Buy | 4.31 | 738,900 | 3,186,950 | 2,000,000 | Jun 06 05:10 PM | | Vukovic Vojo | SVP, Chief Medical Officer | Jun 05 | Buy | 4.58 | 10,000 | 45,800 | 35,249 | Jun 06 05:04 PM | | Kovner Bruce | Director | Jun 05 | Buy | 4.71 | 756,000 | 3,561,743 | 1,261,100 | Jun 06 05:10 PM | | Kovner Bruce | Director | Jun 04 | Buy | 4.99 | 505,100 | 2,521,661 | 505,100 | Jun 06 05:10 PM | | WILSON ROBERT N | Director | Jun 04 | Buy | 5.00 | 10,000 | 50,000 | 699,679 | Jun 06 05:01 PM | | Gollust Keith R | Director | Jan 23 | Option Exercise | 8.66 | 114,250 | 989,603 | 316,255 | Jan 24 04:59 PM | | Kovner Bruce | Director | Nov 14 | Buy | 6.95 | 10,500 | 73,009 | 947,700 | Nov 14 06:48 PM | | Kovner Bruce | Director | Nov 14 | Buy | 6.95 | 10,500 | 73,009 | 947,700 | Nov 14 06:45 PM | | Bahcall Safi R | President and CEO | Nov 12 | Buy | 7.12 | 10,000 | 71,200 | 2,373,135 | Nov 13 09:06 AM | | Kovner Bruce | Director | Nov 12 | Buy | 6.89 | 27,200 | 187,449 | 937,200 | Nov 14 06:45 PM | | Kovner Bruce | Director | Nov 12 | Buy | 6.89 | 27,200 | 187,449 | 937,200 | Nov 14 06:48 PM | | Kovner Bruce | Director | Jun 29 | Buy | 5.45 | 910,000 | 4,959,318 | 6,816,048 | Jul 02 04:53 PM | | Gollust Keith R | Director | Jun 29 | Buy | 5.35 | 150,000 | 801,900 | 1,827,967 | Jul 02 02:45 PM | | Bahcall Safi R | President and CEO | Jun 29 | Buy | 5.34 | 10,000 | 53,370 | 2,343,135 | Jul 02 08:53 AM | | Vukovic Vojo | SVP, Chief Medical Officer | Jun 29 | Buy | 5.59 | 3,000 | 16,755 | 25,249 | Jul 02 08:53 AM |
|
|
|
|
|
|
